AUS
NZ
UK
CA
USA
IND
Highlights
Prescient Therapeutics (ASX:PTX) advances its PTX-100 clinical trial after FDA Fast Track status
Company secures funding via Share Purchase Plan to support ongoing development
Expansion of trial sites in Australia, US, and Europe continues to progress
Prescient Therapeutics Ltd (ASX:PTX), listed on the ASX 300, is progressing its lead targeted therapy PTX-100 following Fast Track designation by the US Food and Drug Administration. The therapy is being developed for cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma with limited existing treatment options.
The designation enables streamlined regulatory interaction, including rolling submissions for potential approval pathways. In response to the regulatory milestone, Prescient initiated its Phase 2a clinical trial, which focuses on assessing efficacy and safety in patients with relapsed or treatment-resistant CTCL.
Trial Expansion Underway Across Multiple Regions
The Phase 2a trial commenced dosing with two active sites in Australia and plans to activate additional centres in the US and Europe. The open-label study aims to enroll approximately forty participants and test two dosage levels of PTX-100.
This global expansion is intended to generate a robust data set to inform further clinical development. The trial will continue to monitor patient outcomes and treatment responses while further sites are being brought online.
Financial Position Strengthened by Share Purchase Plan
Prescient closed the previous financial quarter with a solid cash reserve, later boosted by additional capital raised through a Share Purchase Plan. The funds are designated to support the advancement of PTX-100 and broader pipeline activities.
Net operating outflows primarily directed towards research and development contributed to cash usage over the quarter. The company also commenced a follow-on placement targeting institutional participants under a trading halt.
Additional Focus on Peripheral T-Cell Lymphoma and Cell Therapy Platforms
While CTCL remains the core indication for PTX-100, Prescient continues evaluating data opportunities in peripheral T-cell lymphoma (PTCL), another rare and aggressive condition. This parallel effort supports the broader development potential of its oncology pipeline.
The company’s CellPryme-M platform—engineered to improve cell therapy performance—is also undergoing validation through multiple external collaborations. Meanwhile, technical work continues on OmniCAR, a universal immune receptor platform, with positive early-stage preclinical outcomes reported.
Board Appointment Enhances Governance Capability
During the reporting period, Prescient appointed Melanie Farris as an independent non-executive director. Farris brings governance experience from roles at biotech companies including Telix Pharmaceuticals Ltd and Invion Ltd. She now chairs Prescient’s audit and risk committee, contributing to board oversight and risk management processes.
Prescient’s strengthened leadership and capital position come at a pivotal moment as the company accelerates its clinical development efforts for targeted cancer treatments.
Frequently Asked Questions
- What is the focus of Prescient Therapeutics' latest clinical trial?
Prescient Therapeutics (ASX:PTX) is conducting a Phase 2a trial for PTX-100 to treat cutaneous T-cell lymphoma (CTCL). - Why did Prescient receive FDA Fast Track designation?
The Fast Track status recognises PTX-100’s development for a serious condition with limited treatments, enabling expedited regulatory processes. - How is Prescient funding its ongoing cancer drug development?
The company completed a Share Purchase Plan and initiated a placement to support the advancement of PTX-100 and related programs.
